Form 13-F position report

EDGEWISE THERAPEUTICS INC

Reported by DAFNA Capital Management LLC

EWTX CUSIP 28036F105 Manager CIK 0001389933

Reported 226,819 shares, up 114,583 (102.1%) from the prior quarter.

Reported value 160.7%; share count 102.1% vs. the prior quarter.

Added
% of reported 13F value 1.76% This manager · Q2 2026
Shares 226,819 Quarter-end amount reported
Reported value $9,215,656 Fair value at quarter end
Consecutive quarters held 18 Through Q2 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 3460000
2022-06-30 5540000
2022-09-30 7686000
2022-12-31 6855576
2023-03-31 4890704
2023-06-30 4025226
2023-09-30 2976070
2023-12-31 4916261
2024-03-31 5585033
2024-06-30 5226448
2024-09-30 6082811
2024-12-31 4996638
2025-03-31 4029080
2025-06-30 3122015
2025-09-30 3466798
2025-12-31 3963849
2026-03-31 3535434
2026-06-30 9215656
2026-09-30 9005851

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for EDGEWISE THERAPEUTICS INC held by DAFNA Capital Management LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 221,819 -5,000 (-2.2%) 1.92% $9,005,851 2026-11-16
Q2 2026 Added 226,819 +114,583 (102.1%) 1.76% $9,215,656 2026-08-14
Q1 2026 Reduced 112,236 -47,500 (-29.7%) 0.8% $3,535,434 2026-05-15
Q4 2025 Reduced 159,736 -54,000 (-25.3%) 0.92% $3,963,849 2026-02-17
Q3 2025 Reduced 213,736 -24,404 (-10.2%) 0.86% $3,466,798 2025-11-14
Q2 2025 Added 238,140 +55,000 (30.0%) 0.86% $3,122,015 2025-08-14
Q1 2025 Reduced 183,140 -4,000 (-2.1%) 1.14% $4,029,080 2025-05-15
Q4 2024 Reduced 187,140 -40,766 (-17.9%) 1.27% $4,996,638 2025-02-14
Q3 2024 Reduced 227,906 -62,291 (-21.5%) 1.44% $6,082,811 2024-11-14
Q2 2024 Reduced 290,197 -16,000 (-5.2%) 1.25% $5,226,448 2024-08-14
Q1 2024 Reduced 306,197 -143,187 (-31.9%) 1.27% $5,585,033 2024-05-15
Q4 2023 Reduced 449,384 -70,000 (-13.5%) 1.18% $4,916,261 2024-02-14
Q3 2023 Unchanged 519,384 0 (0.0%) 0.93% $2,976,070 2023-11-14
Q2 2023 Reduced 519,384 -213,855 (-29.2%) 1.1% $4,025,226 2023-08-14
Q1 2023 Reduced 733,239 -33,604 (-4.4%) 1.47% $4,890,704 2023-05-15
Q4 2022 Reduced 766,843 -14,269 (-1.8%) 1.93% $6,855,576 2023-02-14
Q3 2022 Added 781,112 +85,153 (12.2%) 2.07% $7,686,000 2022-11-14
Q2 2022 Added 695,959 +339,209 (95.1%) 1.51% $5,540,000 2022-08-15
Q1 2022 New 356,750 +356,750 (0.0%) 0.9% $3,460,000 2022-05-16

Who else reported the position

254 managers reported EDGEWISE THERAPEUTICS INC for Q2 2026.

Managers reporting EDGEWISE THERAPEUTICS INC in Q2 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Unchanged 15,518,492 0 11.75% $630,516,330 22 qtrs
Paradigm Biocapital Advisors LP Added 10,215,455 +2,850,417 7.77% $415,053,937 10 qtrs
RA CAPITAL MANAGEMENT L P Reduced 8,392,730 -2,035,707 2.96% $340,996,620 10 qtrs
BlackRock Inc Added 6,606,336 +133,345 < 0.01% $268,415,431 8 qtrs
Jupiter Topco LLC New 6,075,331 +6,075,331 0.1% $246,945,299 1 qtr
FMR LLC Added 5,489,135 +4,472,083 < 0.01% $223,023,556 22 qtrs
Novo Holdings A S Unchanged 5,350,000 0 12.62% $217,370,500 22 qtrs
DRIEHAUS CAPITAL MANAGEMENT LLC Added 4,728,623 +250,681 1.11% $192,123,952 11 qtrs
PERCEPTIVE ADVISORS LLC Reduced 4,373,974 -50,000 2.67% $177,714,564 11 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 3,860,670 +72,509 < 0.01% $156,859,022 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2026
Filed
August 14, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
226,819
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.